絞り込み

17394

広告

腸内ウイルス由来の酵素で原因菌を破壊 大阪市大と東大の研究チーム (毎日新聞)

[PR] 腸内細菌のウイルス感染状況を網羅的に調べることで、偽膜性腸炎の原因菌を破壊する抗菌物質を見つけ出す方法を開発したと、大阪市大と東京大の研究チームが発表...

  1. アビガン、有効性判断できず 藤田医大が臨...
  2. 「療養状況等及び入院患者受入病床数等に関...
  3. SBをスタンドで応援する犬型ロボット そ...
  4. 接触確認アプリ(COCOA)に陽性者とし...

ニュース一覧

Treatment of Cancer-Associated Thrombosis: Beyond HOKUSAI.

著者 Mahé I , Elalamy I , Gerotziafas GT , Girard P
TH Open.2019 Jul ; 3(3):e309-e315.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (54view , 0users)

Full Text Sources

Direct oral anticoagulants (DOACs) represent an attractive alternative to low-molecular-weight heparins (LMWHs) for the long-term treatment of cancer-associated thrombosis (CT) since they avoid the burden of daily injections. Analyses in subgroups of cancer patients from large randomized trials suggested that DOACs were at least as effective as vitamin K antagonists, while indirect comparisons suggested that DOACs' efficacy and safety profile were comparable to those of LMWHs. In the randomized controlled HOKUSAI-VTE Cancer study, currently the only completed phase III trial on DOACs in CT patients, edoxaban was shown noninferior to dalteparin on the composite primary endpoint of time to first recurrent venous thromboembolism or major bleeding during the 12 months after randomization. Study results suggest that both agents had comparable benefit/risk ratio in patients with CT. Even though this conclusion was valid from a strict statistical viewpoint, it was potentially misleading when interpreting benefit/risk ratios. Besides the obvious heterogeneity of the study population (e.g., 23% of patients no longer had cancer) and significantly different treatment durations between arms, secondary outcomes for efficacy were in favor of edoxaban for recurrent deep-vein thrombosis but not for recurrent pulmonary embolism, and major bleeding episodes were significantly more frequent in the edoxaban group, with an excess of gastrointestinal (GI) bleeding episodes observed mainly but not only in patients with GI cancers. More research is needed regarding specific patients' profiles, cancer types, and treatment period to better clarify the respective roles of DOACs and LMWHs in CT patients.
PMID: 31535076 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード